NCT02695641 - Reduction of Plasma Free VEGF-A Using Low-dose Bevacizumab in Hemodialysis Patients | Biotech Hunter

Timeline

Start Date

August 1, 2019

Primary Completion Date

August 31, 2020

Study Completion Date

November 30, 2021

Conditions

End Stage Renal DiseaseHemodialysis Vascular Access Failure

Interventions

DRUG

1.25mg bevacizumab

Bevacizumab is a monoclonal antibody against VEGF-A. 1.25mg in 50ml 0.9% Sodium Chloride will be administered once as an intravenous infusion over 30 minutes.

DRUG

2.50mg bevacizumab

Bevacizumab is a monoclonal antibody against VEGF-A. 2.50mg in 50ml 0.9% Sodium Chloride will be administered once as an intravenous infusion over 30 minutes.